Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603392 Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHSE:603392
49 GF Score
Price ¥25.50
GF Value ¥50.26
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Beijing Wantai Biological Pharmacy Enterprise Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Beijing Wantai Biological Pharmacy Enterprise Co is: High Risk: Sensitive to economic or industry trends.

Beijing Wantai Biological Pharmacy Enterprise Co  (SHSE:603392) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Beijing Wantai Biological Pharmacy Enterprise Co Risk Assessment Related Terms

SHSE:603392 vs VRTX, REGN, MRNA: Risk Assessment Comparison

For the Biotechnology subindustry, Beijing Wantai Biological Pharmacy Enterprise Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beijing Wantai Biological Pharmacy Enterprise Co Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Wantai Biological Pharmacy Enterprise Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Beijing Wantai Biological Pharmacy Enterprise Co's Risk Assessment falls into.


SHSE:603392
49GF Score
Beijing Wantai Biological Pharmacy Enterprise Co Ltd SHSE:603392
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co stock appears to be undervalued. The current stock price of ¥25.50 is trading 49.3% below its estimated GF Value™ of ¥50.26. GuruFocus considers Beijing Wantai Biological Pharmacy Enterprise Co to be Possible Value Trap.

Key valuation signals for SHSE:603392:

  • Risk Assessment:
  • GF Value™: ¥50.26 vs. price of ¥25.50 (49.3% below fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603392 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Wantai Biological Pharmacy Enterprise Co Business Description

Address No. 31, Science Park Road, Changping District, Beijing, CHN, 102206
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
49GF Score

Get the complete analysis for SHSE:603392

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥25.50
Price
¥50.26
GF Value